Skip to main content

Table 2 Clinical characteristics of DM patients with satisfactory (HbA1c < 6.5%) or poor (HbA1c≥6.5%) glycemic control

From: Impact of glycemic control on circulating endothelial progenitor cells and arterial stiffness in patients with type 2 diabetes mellitus

  HbA1c < 6.5%
(n = 120)
HbA1c≥6.5%
(n = 114)
P-value
Age, years 56.5 ± 8.5 56.8 ± 8.4 0.81
Males, n (%) 62 (52) 57 (50) 0.35
Hypertension, n (%) 40 (33) 58 (51) < 0.05
Hypercholesterolemia, n (%) 52 (43) 62 (54) < 0.01
Ever-smokers, n (%) 29 (24) 43 (38) < 0.01
Duration of DM, yrs 9.7 ± 7.0 10.3 ± 8.6 0.37
Body-mass index, kg/m2 25.4 ± 4.3 24.9 ± 5.2 0.48
Waist-hip circumference ratio 0.9 ± 0.1 0.9 ± 0.1 0.38
Body weight, kg 64.2 ± 11.7 65.6 ± 10.3 0.52
Systolic blood pressure, mmHg 145.2 ± 23.2 143.1 ± 18.5 0.45
Diastolic blood pressure, mmHg 77.9 ± 7.8 80.4 ± 9.5 0.08
Fasting blood glucose, mmol/L 5.7 ± 1.2 8.5 ± 2.3 < 0.01
HbA1c, % 6.1 ± 0.5 8.8 ± 1.3 < 0.01
Triglyceride, mmol/L 1.5 ± 1.1 1.7 ± 1.3 0.18
Total cholesterol, mmol/L 4.6 ± 0.9 4.5 ± 0.9 0.27
LDL-C, mmol/L 2.6 ± 0.8 2.5 ± 0.7 0.21
HDL-C, mmol/L 1.3 ± 0.4 1.2 ± 0.4 0.06
Creatinine, μmol/L 82.8 ± 21.6 85.7 ± 31.0 0.42
GFR, ml/min/1.73m2 56.4 ± 12.1 55.0 ± 17.2 0.39
Beta-blocker, n (%) 56 (47) 50 (44) 0.34
Calcium channel blocker, n (%) 35 (29) 42 (37) 0.08
ACEI/ARB, n (%) 57 (48) 65 (57) 0.06
Aspirin, n (%) 48 (40) 55 (48) 0.13
Statin, n (%) 57 (48) 62 (54) 0.11
Insulin, n(%) 9 (8) 26 (23) < 0.01
Log CD34/KDR+ EPCs, 10-3/ml 1.05 ± 0.27 0.88 ± 0.32 < 0.01
Log CD133/KDR+ EPCs, 10-3/ml 0.78 ± 0.28 0.61 ± 0.21 < 0.01
Log baPWV, cm/s 3.23 ± 0.08 3.27 ± 0.09 < 0.05
  1. Abbreviations as in Table 1